C
Capricor Therapeutics, Inc. (CAPR)
NMS – Real vaqt narxi. Valyuta: USD
31.52
-0.38 (-1.19%)
Yopilishda: May 12, 2026, 4:00 PM EDT
32.24
+0.72 (2.30%)
Bozor oldidan: May 13, 2026, 7:47 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
31.52
-0.38 (-1.19%)
Yopilishda: May 12, 2026, 4:00 PM EDT
32.24
+0.72 (2.30%)
Bozor oldidan: May 13, 2026, 7:47 AM EDT
Capricor Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Duchenne mushak distrofiyasi (DMD) va Qo'shma Shtatlardagi boshqa tibbiy ehtiyojlari qondirilmagan kasalliklarni davolash uchun transformativ hujayra va ekzomaga asoslangan terapevtik vositalarni ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsulot nomzodi Deramiocel, allogenik kardiosfera hosilasi bo'lgan hujayralar bo'lib, u DMDni davolash uchun 3-bosqichli klinik sinovdan o'tmoqda. Kompaniya, shuningdek, SARS-CoV-2ni davolash uchun preklinik sinovda bo'lgan ekzomali oqsilga asoslangan vaktsinani ishlab chiqadi; StealthX Exosome Platform va vaktsina va terapevtik vositalarni ishlab chiqish uchun muhandislik qilingan ekzomalardan iborat ekzom platformasi dasturi preklinik sinovda. Bundan tashqari, u turli kasalliklarni davolash yoki oldini olish uchun maqsadli RNK, oqsil va kichik molekulali terapevtik vositalarni o'z ichiga olgan bir qator terapevtik qo'llash uchun 1-bosqichli klinik tadqiqotda muhandislik qilingan ekzomaga asoslangan vaktsina nomzodi bo'lgan StealthXni ishlab chiqish bilan shug'ullanadi; barcha sohalarda litsenziyalangan patent huquqlari va nou-xau bo'yicha nom-eksklyuziv huquq ostida litsenziyalangan mahsulotlar va litsenziyalangan xizmatlarni ishlab chiqish va tijoratlashtirish uchun Johns Hopkins universiteti, Rim universiteti va Cedars-Sinai tibbiyot markazi bilan litsenziyalash shartnomasiga ega; ekzom platformasini ishlab chiqish uchun Life Technologies bilan hujayra liniyasi litsenziyalash shartnomasi. Kompaniya 2005 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning San-Diego shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Catherine Lee Kelleher M.D. | Consultant |
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Operating & Science Officer |
| Dr. Linda Marbán Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Micheal Binks M.D. | Chief Medical Officer |
| Mr. Anthony J. Bergmann M.B.A. | CFO & Corporate Treasurer |
| Mr. Mark Awadalla | Chief Development Officer |
| Mr. Minghao Sun Ph.D. | Senior Vice President of Quality Control, Research & Product Development |
| Ms. Karen G. Krasney Esq., J.D. | Executive VP, General Counsel & Secretary |
| Nathaniel Hogan Ph.D. | Director of Biostatistics of Capricor Therapeutics |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | capr-20260507x8k.htm |
| 2026-04-10 | DEF 14A | capr-20260604xdef14a.htm |
| 2026-04-10 | ARS | tm263892d3_ars.pdf |
| 2026-03-31 | PRE 14A | capr-20250522xpre14a.htm |
| 2026-03-17 | 10-K | capr-20251231x10k.htm |
| 2026-03-12 | 8-K | capr-20260312x8k.htm |
| 2026-03-10 | 8-K | capr-20260310x8k.htm |
| 2026-01-30 | S-8 | capr-20260130xs8.htm |
| 2025-12-05 | 8-K | capr-20251205x8k.htm |
| 2025-12-03 | 8-K | capr-20251203x8k.htm |